Effect of High Intensity Interval Exercise Training in Patients With Allergic Rhinitis

NCT06543251 | Completed DMC

• 1 other identifier: EX PHYSIO SPSC 11
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study was to compare the effects of training between high-intensity interval training and moderate continuous exercise training on the pulmonary function, respiratory muscle strength, symptoms of patients with allergic rhinitis, cytokines, and oxidative stress in patients with allergic rhinitis.

Conditions

Allergic Rhinitis

Keywords

Allergic rhinitis; Aerobic exercise; High intensity interval training; pulmonary function; cytokines

Outcome Measures

Primary Outcomes (7)

• Rhinitis symptom scores

  Nasal symptoms were assessed using Total Nasal Symptom Score (TNSS) questionnaire. The subjects were asked to score symptoms of persistent allergic rhinitis before and after yoga training protocol. The total nasal symptom scores were computed as the sum of four individual nasal symptom scores; nasal congestion, itching, sneezing, and rhinorrhea. The scores ranged from 0 to 3 scale (0=none, 1=mild, 2=moderate, 3= severe)

  Change from Baseline Rhinitis symptom scores at 12 weeks.

• Peak nasal inspiratory flow

  The subjects placed a mask, which is turned onto a plastic cylinder through which the air passes during inspiration, over the nose and mouth and inspired forcefully through the nose, with lips tightly closed. Inside the cylinder, there is a diaphragm that moves to the airflow, and the maximum peak flow is registered in a scale range from 30-370 L/min. During the procedure, the subjects placed a mask over the nose and mouth and inspired forcefully through the nose, with lips tightly closed.

  Change from Baseline Peak nasal inspiratory flow scores at 12 weeks.

• Nasal blood flow

  Laser Doppler flowmetry (DRT4 moor instrument, UK.) was used to measure of the nasal blood flow (NBF). Before the test each subject rested for one hour in a separate room. During the test, they were instructed to breathe normally breathe and not to speak, cough, or move. A lateral endoscopic probe with a flexible nylon sheath 1.34-mm-diameter flexible nylon sheath was placed to the front of the nose.

  Change from Baseline Nasal blood flow scores at 12 weeks.

• Pulmonary Functions

  The participants were asked to wear a nose clip while sitting on a chair, and the researcher gave the participants the step-by-step protocol to prevent an incorrect maneuver. For the FVC maneuver, three cycles of slow normal breathing were performed before demonstrating forced inspiration and expiration.

  Change from Baseline Pulmonary Functions at 12 weeks.

• Respiratory muscle strength

  Respiratory muscle strength was assessed by measuring Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) in cmH2O. The participants were in a sitting position using a portable handheld mouth pressure meter (i.e., MicroRPM) with a nose clip. For the MIP measurement, the participants were asked to exhale until they felt no air remaining in their lungs (starting with the functional residual capacity \[FRC\] point), then held the device on their mouth and inhaled forcefully for 1-2 seconds. For the MEP measurement, the participants were asked to inhale until their lungs were completely filled with air (starting with the total lung capacity \[TLC\] point), then they kept the device on their mouth and exhaled forcefully for 1-2 seconds

  Change from Baseline Respiratory muscle strength at 12 weeks.

• Fraction exhaled nitric oxide

  Participants inhaled deeply for two to three seconds before exhaling slowly. Normally, it took 10 seconds to exhale.

  Change from Baseline Fraction exhaled nitric oxide at 12 weeks.

• Aerobic capacity

  Aerobic capacity variables were measured by determining maximum oxygen uptake (VO2max) using the Bruce protocol. The subjects ran on a treadmill. At the beginning of the test, the baseline or resting value was collected for the first 3 minutes. The initial speed was set at step 1 (minutes 0-3) at a speed of 1.7 mph with a 10% incline. The test was incremented every 3 minutes. Step 2 (minutes 4-6) was conducted at a speed of 2.5 mph with a 2% incline. The test continued until the subjects could not run any further. Following this, the subjects were cooled down for 3 minutes. The maximum oxygen uptake was measured in milliliters per kilogram per minute (ml/kg/min).

  Change from Baseline Aerobic capacity at 12 weeks.

Secondary Outcomes (2)

• Cytokine in nasal secretion

  Change from Baseline Cytokine in nasal secretion at 12 weeks.

• Rhinoconjunctivitis quality of life questionnaire - 36; Rcq-36

  Change from Baseline quality of life at 12 weeks.

Study Arms (3)

High-intensity interval training group (HIIT)

EXPERIMENTAL

the group with high-intensity interval training at a ratio of 1:2 (HIIT) 3 days per week, over a total period of 12 weeks.

Other: High-intensity interval training group (HIIT)

Moderate continuous training group (MCT)

EXPERIMENTAL

the group with moderate continuous training, 3 days per week, over a total period of 12 weeks.

Other: Moderate continuous training group (MCT)

Sedentary control group (CON)

OTHER

Other: Sedentary control group (CON)

Interventions

High-intensity interval training group (HIIT) OTHER

The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.

High-intensity interval training group (HIIT)

Moderate continuous training group (MCT) OTHER

Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.

Moderate continuous training group (MCT)

Sedentary control group (CON) OTHER

The control group had normal daily life.

Sedentary control group (CON)

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• A patient with allergic rhinitis who underwent a skin prick test and received a positive result.
• Patients with persistent allergic rhinitis, male and female, with symptoms of nasal congestion, sneezing, nasal itching, and runny nose for more than 4 days per week, and an average score of 7 or more in the past week using the allergic rhinitis symptom assessment questionnaire.
• stopped taking all medicine before the study such as antihistamine for 3 days, oral steroid and nasal steroid for at least 2 weeks and leukotriene receptor antagonist for at least a week prior to the study
• had no exercise program, non-smoking and without any food supplementation for at least 6 months prior to the start of the study
• Must not have other respiratory diseases such as bronchitis, pertussis, pneumonia, pneumonitis, aspergilloma, tuberculosis, asthma, lung cancer, emphysema, etc.
• Have a body mass index (BMI) between 18.5 and 24.9 kg/m².
• Complete the Physical Activity Readiness Questionnaire (PAR-Q+) by answering "no" to all questions.

You may not qualify if:

• There is an unforeseen circumstance, such as an illness, that prevents participation in the research.
• Less than 80% of the research was completed.

Sponsors & Collaborators

• Chulalongkorn University: lead

Study Sites (1)

Faculty of Sports Science, Chulalongkorn University

Pathum Wan, Bangkok, 10330, Thailand

Location

MeSH Terms

Conditions

Rhinitis, Allergic

Condition Hierarchy (Ancestors)

Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Wannaporn Tongtako, Ph.D.

  Chulalongkorn University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: August 4, 2024
• First Posted: August 7, 2024
• Study Start: June 1, 2023
• Primary Completion: September 25, 2023
• Study Completion: October 15, 2023
• Last Updated: August 7, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

TH (1)